Tonix Pharmaceuticals Announced Data Supporting The Memory- And Cognition-enhancing Effects Of TNX-601 ER (Tianeptine Hemioxalate Extended Release) And TNX-4300 (Estianeptine), The Single (s)-isomer Of Tianeptine
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals announced data supporting the memory- and cognition-enhancing effects of TNX-601 ER and TNX-4300. TNX-601 ER is being tested for the treatment of major depressive disorder, with results expected in Q1 2024. TNX-4300 is in preclinical development for mood disorders, Alzheimer's disease, and Parkinson's disease. The findings suggest a role for PPAR-β/δ activation in memory.
July 24, 2023 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' TNX-601 ER and TNX-4300 show promising results in enhancing memory and cognition. This could potentially boost the company's stock in the short term.
The announcement of positive data from Tonix Pharmaceuticals' TNX-601 ER and TNX-4300 trials could potentially increase investor confidence in the company, leading to a short-term increase in the company's stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100